Working… Menu

PET Response During Chemoradiation of Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02315053
Recruitment Status : Completed
First Posted : December 11, 2014
Last Update Posted : October 27, 2017
Information provided by (Responsible Party):
The Netherlands Cancer Institute

Brief Summary:
A prospective observational study to determine the prognostic value of the timing of 50% reduction in metabolic activity (T50) during CCRT for NSCLC for treatment outcome (PFS).

Condition or disease Intervention/treatment Phase
NSCLC Other: Low dose FDG PET/CT 5 x. Not Applicable

Detailed Description:
This is a single-centre observational study. Patients with proven locally advanced NSCLC will be treated with concurrent chemoradiotherapy according to the standard clinical protocol of the NKI-AVL. During treatment, the biological behaviour of the tumour will be monitored with serial quantitative FDG (fluorodeoxyglucose) PET/CT scans. From these images, the time during treatment where a 50% reduction in FDG uptake relative to day 1 is reached (T50) will be derived. The T50 of progression-free surviving patients will be compared with that of relapsed or deceased patients, in order to find a value that predicts early treatment failure. An additional FDG PET/CT scan at the same day as regular follow up CT scan will be made, two months after treatment, to have a baseline after treatment for follow up.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dynamic FDG-PET/CT Response During Chemoradiation for NSCLC
Actual Study Start Date : March 21, 2013
Actual Primary Completion Date : September 2017
Actual Study Completion Date : September 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Low dose FDG PET/CT 5x
Stage II/III NSCLC will undergo a Low dose FDG PET/CT 5x during treatment (CCRT).
Other: Low dose FDG PET/CT 5 x.
Multiple FDG PET/CT studies will be added to the normal diagnostic procedures as a part of this study, with the number of scans depending on the study stage, to a maximum of 6 per patient.
Other Name: No treatment intervention but diagnostic intervention.

Primary Outcome Measures :
  1. maximum FDG uptake (SUVmax) [ Time Frame: 1 Year ]
    • A main study parameter is the maximum FDG uptake (SUVmax (maximum Standardized Uptake Value)) at the location of the primary tumour, as determined at multiple days during treatment (with a maximum of five time points per patient), expressed as T50 for response evaluation.

Secondary Outcome Measures :
  1. SUVmax during the first two weeks of treatment, indicating inflammatory response. [ Time Frame: First Two weeks of treatment ]
    • Increase SUVmax during the first two weeks of treatment, indicating inflammatory response.

  2. SUVmax in the two weeks prior to treatment, indicating progression [ Time Frame: Two weeks prior to treatment ]
    • Increase SUVmax between diagnostic imaging and start of treatment, indicating potential progression.

  3. Progression free survival [ Time Frame: 1 Year ]
    • Secondary study endpoint is progression free survival, to be associated with T50 for prognostic value.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cytologically or histologically proven NSCLC
  • T2-4 N0-3 M0 disease (stage II or III, inoperable)
  • Scheduled for standard concurrent chemoradiation
  • Primary tumour minimal diameter 3 cm
  • Primary tumour SUVmax > 5 on routine diagnostic pre-treatment FDG (Fludeoxyglucose) PET/CT
  • WHO performance 0-1
  • Written informed consent according to GCP (Good Clinical Practice) and national regulations

Exclusion Criteria:

  • Age < 18 years, incapacitated subjects
  • Pregnant or lactating women
  • Diabetes mellitus requiring medication
  • Participation in dose escalation studies
  • Other neoplasms in the last 3 years, with metastases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02315053

Layout table for location information
The Netherlands Cancer Institute
Amsterdam, Noord Holland, Netherlands, 1066CX
Sponsors and Collaborators
The Netherlands Cancer Institute
Layout table for investigator information
Principal Investigator: Wouter Vogel, MD,PhD NKI
Layout table for additonal information
Responsible Party: The Netherlands Cancer Institute Identifier: NCT02315053    
Other Study ID Numbers: N12LPR
First Posted: December 11, 2014    Key Record Dates
Last Update Posted: October 27, 2017
Last Verified: October 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by The Netherlands Cancer Institute: